Patent Application
20140275138
The present invention relates to the treatment of Type 2 diabetes. Type 2 diabetes is usually caused by an increase in insulin resistance, wherein insulin interaction with its cell receptor is either interfered with, or fails to elicit the normal downstream reactions which lower blood glucose levels. Type 2 diabetes is treated with drugs which
(1) stimulate the pancreas to produce and release more insulin,
(2) inhibit the production and release of glucose from the liver,
(3) blocking the action of stomach enzymes that break down carbohydrates, or
(4) improving the sensitivity of cells to insulin.
In the present invention, diabetes is treated by the administration of particular members of the d-tetrandrine family of drugs. The d-tetrandrine family members have the following structural formula:
Where R1 and R1′ are the same or different shortchained carbon based ligand including without limitation, CH3, CO2CH3 or H; and R2 is CH3 or C2H5; and R3 is CH3 or hydrogen; and where the chemical structure has the “S” isomeric configuration at the C-1′ chiral carbon location. The treatment may involve treatment with the d-tetrandrine family member only, or in conjunction with other drugs used to treat diabetes.
The preferred members of the d-tetrandrine family include the following representative examples, which are not intended to be exhaustive: d-tetrandrine, isotetrandrine, hernandezine, berbamine, pycnamine, phaeanthine, obamegine, ethyl fangchinoline and fangchinoline. In all of these examples, R1 and R1′ constitute the methyl group. Variation within the group occurs in that R2 and R3 may constitute either a methyl group or hydrogen, and the isometric configuration of the compounds at the C-1 and C-1′ chiral carbon positions is either R (rectus) or S (sinister). The rules for R and S configuration can be bound in Morrison and Boyd, “Organic Chemistry,” 4th Edition, copyright 1983 by Allyn and Bacon, at pp. 138-141. As noted above, the chiral configuration at C-1 is “S” for members of the d-tetrandrine family. In addition, hernandezine includes a methoxy group at the C-5 position.
The most preferred member of the claimed d-tetrandrine family is d-tetrandrine. Methods for extracting and/or purifying d-tetrandrine are disclosed in U.S. Pat. No. 6,218,541 and in Published Patent Application No. 2011/0105755.
While not wishing to be bound by a particular theory on mode of operation, it is believed that the d-tetrandrine family member acts to improve the sensitivity of cells to insulin. As such, the d-tetrandrine family member can be administered alone as a Type 2 diabetes treatment.
However, the d-tetrandrine family member can also be administered concurrently with a secondary Type 2 diabetes medication. The most preferred drug to be administered concurrently would be one of the drugs which act to improve the sensitivity of cells to insulin. Similarly, there are dietary supplements which mediate diabetes. The d-tetrandrine family member can also be administered concurrently with such dietary supplements.
In the case of concurrent administration, the d-tetrandrine family member and the secondary diabetes drug or dietary supplement can be formulated together into a single formula, or they can be formulated separately and administered either simultaneously or sufficiently close together that they are both in the target cell area at the same time. The d-tetrandrine family member and the diabetes drug or dietary supplement can be formulated separately and be sold as part of a “kit.” The usage ratio of the d-tetrandrine family member to a diabetes drug or dietary supplement will vary from patient to patient and as a function of the secondary drug or dietary supplement used, within a range of about 10:90 to 90:10, but more preferably from about 25:75 to 75:25.
It is believed that the optimum dosage procedure would be to administer the d-tetrandrine family member in oral doses of from about 50 to about 1000 mg per square meter per day, more preferably 250-700, and most preferably about 500, (probably in two to four doses per day). For concurrent administration, a secondary diabetes drug or dietary supplement would preferably be administered simultaneously or on the same day. The dosage level for the d-tetrandrine family member will vary from case to case, based on the patient and on the drug or dietary supplement used. The drug or dietary supplement is administered at usual dosage levels (possibly somewhat less in view of the effect of the tetrandrine family member) once or more during the course of the d-tetrandrine family member dosing.
The d-tetrandrine family bisbenzylisoquinolines have two nitrogen locations and hence can exist in the free base form or as a mono or di-acid salt. Because of the enhanced solubility of the salt form of pharmaceutical ingredients, the salt forms are used in formulating pharmaceutical compositions. The active ingredient thus solubilizes more quickly and enters the bloodstream faster. The free base form is not soluble in water. However, it has recently been surprisingly found by a co-worker that the free base formulations of d-tetrandrine family members are absorbed into the bloodstream substantially as rapidly as formulations of the di-acid salt members of the family. Accordingly, we propose to use either the free base or the di-acid salt of the d-tetrandrine family member in our formulations.
The preferred formulations comprise a member of the d-tetrandrine family combined with a suitable pharmaceutical carrier. The pharmaceutical carrier can be a liquid or a solid composition. A liquid carrier will preferably comprise water, possibly with additional ingredients such as 0.25% carboxymethylcellulose. The solid carrier or diluent used may be pregelatinized starch, microcrystalline cellulose or the like. It may also be formulated with other ingredients, such as colloidal silicone dioxide, sodium lauryl sulfate and magnesium stearate.
A 200 mg capsule, tablet or liquid dosage formulation is most preferred. The most preferred dose of about 500 mg/square meter/day is roughly 1000 mg per day for a 190 pound patient six feet tall. Such a patient can fulfill the dosage requirements by taking five capsules during the course of the day, for example three in the morning and two in the evening, or one at a time spaced out over the day. A smaller person weighing 125 pounds at a height of five feet six inches would require four 200 mg capsules during the course of the day.
Of course, it is understood that the forgoing are preferred embodiments of the invention, and that variations can be employed without departing from the spirit of the invention as set forth in the appended claims, interpreted in accordance with the principles of patent law.
The present application claims the benefit of U.S. Provisional Patent Application No. 61/798,713, entitled METHOD AND PRODUCTS FOR TREATING DIABETES, filed on Mar. 15, 2013, the entire contents of which are incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61798713 | Mar 2013 | US |
